Background From a registry of 249 confirmed pulmonary embolism (PE) patients submitted to thrombolytic therapy (TT), we analysed predictors of in-hospital course and long-term mortality. Methods and results The combined clinical end point of in-hospital course associated death, recurrent PE, repeat thrombolysis, surgical embolectomy or bleeding complications. The long-term follow-up included analysis of survival, and occurrence of PE-related events, defined as recurrent deep vein thrombosis, recurrent PE, occurrence of congestive heart failure or change of New York Heart Association functional class to class III or IV in patients who survived the acute phase. In-hospital clinical course was uneventful in 165 (66.3%) patients. Initial right ventricular (RV) dysfunction was reversible in 80% within 48 h following TT. Initial pulmonary vascular obstruction >70% (RR=5.3 [2.1; 13.6]); haemodynamic instability at presentation (RR=2.6 [1.1; 6]); persistence of septal. paradoxical motion after TT (RR=5.9 [1.4; 25.9]); and insertion of intracaval filter (RR=3.7 [1.4; 9.4]) were independent predictors of poor in-hospital course. Mean follow-up was 5.3 +/- 2.6 years. Of the 227 patients alive after the hospital stay, the probability of survival was 92% at 1 year, 79% at 3 years and 56% at 10 years. Multivariate predictors of tong-term mortality were age >75 years (RR=2.73 [2.18; 3.21];P=0.0002), persistence of vascular pulmonary obstruction >30% after thrombolytic treatment (RR=2.22 [1.69; 2.74]; P=0.003), and cancer (RR=2.03 [1.40; 2.65]; P=0.04). Conclusion The recovery of RV function should be considered as a marker of thrombolysis efficacy, white residual pulmonary vascular obstruction and cancer are independent predictors of tong-term mortality. These results advocate the identification of high-risk patients by means of systematic lung-scan and echocardiography pre- and post-thrombolysis, and raise the question of the need for thrombo-endarterectomy in patients with residual pulmonary vascular obstruction. (C) 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
机构:
Univ Paris Diderot, Fernand Widal Hosp, AP HP, Clin Res Unit, Paris, FranceUniv Med Ctr, Ctr Thrombosis & Hemostasis, Mainz, Germany
Vicaut, Eric
Danays, Thierry
论文数: 0引用数: 0
h-index: 0
机构:
Boehringer Ingelheim GmbH & Co KG, Reims, FranceUniv Med Ctr, Ctr Thrombosis & Hemostasis, Mainz, Germany
Danays, Thierry
论文数: 引用数:
h-index:
机构:
Becattini, Cecilia
Bertoletti, Laurent
论文数: 0引用数: 0
h-index: 0
机构:
St Etienne Univ Hosp Ctr, Dept Vasc Med & Therapy, St Etienne, France
INSERM, Natl Inst Hlth & Med Res, U1059, St Etienne, France
INSERM, CIC1408, St Etienne, FranceUniv Med Ctr, Ctr Thrombosis & Hemostasis, Mainz, Germany
Bertoletti, Laurent
Beyer-Westendorf, Jan
论文数: 0引用数: 0
h-index: 0
机构:
Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Ctr Vasc Dis, Div Thrombosis Res, Dresden, GermanyUniv Med Ctr, Ctr Thrombosis & Hemostasis, Mainz, Germany
机构:
INNOVTE, Brest, France
Georges Pompidou European Hosp, AP HP, Pulmonol & Intens Care Serv, Paris, France
Paris Descartes Univ, Sorbonne Paris Cite, Paris, France
INSERM, UMR S 1140, Paris, FranceUniv Med Ctr, Ctr Thrombosis & Hemostasis, Mainz, Germany
Sanchez, Olivier
Schellong, Sebastian
论文数: 0引用数: 0
h-index: 0
机构:
Municipal Hosp Dresden Friedrichstadt, Dresden, GermanyUniv Med Ctr, Ctr Thrombosis & Hemostasis, Mainz, Germany
Schellong, Sebastian
Sobkowicz, Bozena
论文数: 0引用数: 0
h-index: 0
机构:
Med Univ, Bialystok, PolandUniv Med Ctr, Ctr Thrombosis & Hemostasis, Mainz, Germany
Sobkowicz, Bozena
Meyer, Guy
论文数: 0引用数: 0
h-index: 0
机构:
INNOVTE, Brest, France
INSERM, UMR S 970, Paris, FranceUniv Med Ctr, Ctr Thrombosis & Hemostasis, Mainz, Germany